PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Saved in:
| Title: | PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. |
|---|---|
| Authors: | Janku F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX., Jegede OA; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA., Puhalla SL; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA., Konstantinopoulos PA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA., Meric-Bernstam F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX., Zwiebel JA; Division of Cancer Treatment and Diagnosis, Investigational Drug Branch, National Cancer Institute, Bethesda, MD., Gray RJ; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA., Wang XV; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA., McShane LM; Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Bethesda, MD., Rubinstein LV; Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Ghani S; University of Oklahoma Health Science Center, Oklahoma City, OK., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2025 Aug; Vol. 9, pp. e2500265. Date of Electronic Publication: 2025 Aug 27. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40865033 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Janku+F%22">Janku F</searchLink>; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Jegede+OA%22">Jegede OA</searchLink>; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Puhalla+SL%22">Puhalla SL</searchLink>; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA.<br /><searchLink fieldCode="AU" term="%22Konstantinopoulos+PA%22">Konstantinopoulos PA</searchLink>; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Zwiebel+JA%22">Zwiebel JA</searchLink>; Division of Cancer Treatment and Diagnosis, Investigational Drug Branch, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Gray+RJ%22">Gray RJ</searchLink>; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wang+XV%22">Wang XV</searchLink>; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22McShane+LM%22">McShane LM</searchLink>; Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Rubinstein+LV%22">Rubinstein LV</searchLink>; Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Patton+DR%22">Patton DR</searchLink>; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Williams+PM%22">Williams PM</searchLink>; Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Hamilton+SR%22">Hamilton SR</searchLink>; City of Hope National Medical Center, Duarte, CA.<br /><searchLink fieldCode="AU" term="%22Takebe+N%22">Takebe N</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Ghani+S%22">Ghani S</searchLink>; University of Oklahoma Health Science Center, Oklahoma City, OK.<br /><searchLink fieldCode="AU" term="%22Tricoli+JV%22">Tricoli JV</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Conley+BA%22">Conley BA</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Harris+LN%22">Harris LN</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Chen+AP%22">Chen AP</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Massachusetts General Hospital Cancer Center, Boston, MA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2025 Aug; Vol. 9, pp. e2500265. <i>Date of Electronic Publication: </i>2025 Aug 27. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40865033 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1200/PO-25-00265 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e2500265 Titles: – TitleFull: PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Janku F – PersonEntity: Name: NameFull: Jegede OA – PersonEntity: Name: NameFull: Puhalla SL – PersonEntity: Name: NameFull: Konstantinopoulos PA – PersonEntity: Name: NameFull: Meric-Bernstam F – PersonEntity: Name: NameFull: Zwiebel JA – PersonEntity: Name: NameFull: Gray RJ – PersonEntity: Name: NameFull: Wang XV – PersonEntity: Name: NameFull: McShane LM – PersonEntity: Name: NameFull: Rubinstein LV – PersonEntity: Name: NameFull: Patton DR – PersonEntity: Name: NameFull: Williams PM – PersonEntity: Name: NameFull: Hamilton SR – PersonEntity: Name: NameFull: Takebe N – PersonEntity: Name: NameFull: Ghani S – PersonEntity: Name: NameFull: Tricoli JV – PersonEntity: Name: NameFull: Conley BA – PersonEntity: Name: NameFull: Arteaga CL – PersonEntity: Name: NameFull: Harris LN – PersonEntity: Name: NameFull: O'Dwyer PJ – PersonEntity: Name: NameFull: Chen AP – PersonEntity: Name: NameFull: Flaherty KT IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2025 Aug Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2473-4284 Numbering: – Type: volume Value: 9 Titles: – TitleFull: JCO precision oncology Type: main |
| ResultId | 1 |
